Acute lymphoblastic leukemia (ALL) is the major pediatric cancer in developed countries. Although treatment outcome has improved owing to advances in chemotherapy, there is still a group of ...

We conducted a phase 1b–2 multicenter study of obe-cel in adults (≥18 years of age) with relapsed or refractory B-cell acute lymphoblastic leukemia ... developed in 7.1% of the patients.

The FDA has approved a new treatment, Aucatzyl, for a type of aggressive blood cancer called B-cell acute lymphoblastic leukemia (B-cell ALL). This treatment, a CAR T-cell immunotherapy ...

The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory acute leukemia with a KMT2A gene translocation in adult and pediatric ...

These changes can be found in both children and adults with AML and acute lymphoblastic ... KMT2A translocations allow a protein called menin to drive cancer growth. By blocking the interaction ...